ILNS Intellect Neurosciences Receives Notice of Allowance from United States Patent and Trademark Office for its ANTISENILIN® Alzheimer's Disease Immunotherapy Technology Platform
USPTO allows claims directed to methods of treating Alzheimer's disease using therapeutic antibodies that recognize the free C-terminus of Beta Amyloid 1-40
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.